bevacizumab,panitumumab
roche,takeda,amgen
[' bev ', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm']
phiii paradigm l-sided #1l mss/ras/braf wt #mcrc w/baseline plasma #ctdna confirming wt/mss median os higher w/pan vs bev but in those w/ras/braf mt, msi-h or r-sided on liquid bx os better w/bev vs pan to folfox (7.2%/10.6%/2.7% ras mt/braf mt/msi-h on ctdna) #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope